Indicators
Indicators
Value
Direction
MACD(12,26,9)
3.176
Buy
RSI(14)
71.303
Buy
STOCH(KDJ)(9,3,3)
74.963
Neutral
ATR(14)
6.432
High Vlolatility
CCI(14)
229.353
Overbought
Williams %R
21.093
Buy
TRIX(12,20)
0.734
Sell
StochRSI(14)
75.276
Buy
Search
Corcept Therapeutics Inc
CORTAdd to Watchlist
114.490USD
-3.830-3.24%
Close 07-31 16:00（ET）Quotes delayed by 15 min
12.36BMarket Cap
249.99P/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-3.24%
5 Days
+20.06%
1 Month
+31.67%
6 Months
+187.16%
Year to Date
+228.99%
1 Year
+70.45%
Key Figures
118.110Open
118.530High
1.84MVolume
249.99P/E TTM
23.91P/E Dynamic
--Dividend TTM
1.71%Turnover Ratio
118.320Prev. Close
111.790Low
157.12MTurnover
87.50P/E Static
17.51P/B
0.00%Div Yield TTM
5.70%ROA
91.00052wk High
0.99Volume Ratio
141.21MNet Profit
107.92MShares
0.4580EPS TTM
0.46Beta
7.17%ROE
28.66052wk Low
5.70%Amplitude
98.41%Gross Margin
12.36BMarket Cap
9.06Reward/Risk
3.44%Risk Rate
TradingKey Stock Score of Corcept Therapeutics Inc
Currency: USD Updated: 2026-07-31Key Insights
Corcept Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 55 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 108.14.In the medium term, the stock price is expected to trend up.Despite a strong stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Corcept Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Corcept Therapeutics Inc Highlights
StrengthsRisks
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 57.85% year-on-year.
Overvalued
The company’s latest PE is 249.99, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 76.88M shares, decreasing 9.91% quarter-over-quarter.
Held by John Hussman
Star Investor John Hussman holds 76.22K shares of this stock.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
108.142
Target Price
+16.34%
Upside Space
Corcept Therapeutics Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
6
analysts
Buy
Current Rating
108.142
Target Price
+16.34%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Corcept Therapeutics Inc
CORT
6
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
33
Pfizer Inc
PFE
32
1
2
3
...
32
Indicators
Moving Average
Indicators
Value
Direction
MA5
102.214
Buy
MA10
98.119
Buy
MA20
94.554
Buy
MA50
83.741
Buy
MA100
63.755
Buy
MA200
61.805
Buy
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Corcept Therapeutics Inc Info
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
Ticker SymbolCORT
CompanyCorcept Therapeutics Inc
CEOBelanoff (Joseph K)
Websitehttps://www.corcept.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-0.92%
-2.51%
+0.32%
-1.45%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
+1.30%
-0.90%
-2.15%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of Corcept Therapeutics Inc (CORT)?
The current price of Corcept Therapeutics Inc (CORT) is 114.44.
What is the symbol of Corcept Therapeutics Inc?
The ticker symbol of Corcept Therapeutics Inc is CORT.
What is the 52-week high of Corcept Therapeutics Inc?
The 52-week high of Corcept Therapeutics Inc is 91.00.
What is the 52-week low of Corcept Therapeutics Inc?
The 52-week low of Corcept Therapeutics Inc is 28.66.
What is the market capitalization of Corcept Therapeutics Inc?
The market capitalization of Corcept Therapeutics Inc is 12.35B.
Is Corcept Therapeutics Inc (CORT) currently rated as Buy, Hold, or Sell?
According to analysts, Corcept Therapeutics Inc (CORT) has an overall rating of Buy, with a price target of 108.14.
What is the Earnings Per Share (EPS TTM) of Corcept Therapeutics Inc (CORT)?
The Earnings Per Share (EPS TTM) of Corcept Therapeutics Inc (CORT) is 0.96.